Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.
;
Julia C
Bennett
;
Maria
Garcia Quesada
;
Eunice W
Kagucia
;
Meagan E
Peterson
;
Daniel R
Feikin
;
Adam L
Cohen
;
Marissa K
Hetrich
;
Yangyupei
Yang
;
Jenna N
Sinkevitch
;
+63 more...
Krow
Ampofo
;
Laurie
Aukes
;
Sabrina
Bacci
;
Godfrey
Bigogo
;
Maria-Cristina C
Brandileone
;
Michael G
Bruce
;
Romina
Camilli
;
Jesús
Castilla
;
Guanhao
Chan
;
Grettel
Chanto Chacón
;
Pilar
Ciruela
;
Heather
Cook
;
Mary
Corcoran
;
Ron
Dagan
;
Kostas
Danis
;
Sara
de Miguel
;
Philippe
De Wals
;
Stefanie
Desmet
;
Yvonne
Galloway
;
Theano
Georgakopoulou
;
Laura L
Hammitt
;
Markus
Hilty
;
Pak-Leung
Ho
;
Sanjay
Jayasinghe
;
James D
Kellner
;
Jackie
Kleynhans
;
Mirjam J
Knol
;
Jana
Kozakova
;
Karl Gústaf
Kristinsson
;
Shamez N
Ladhani
;
Claudia S
Lara
;
Maria Eugenia
León
;
Tiia
Lepp
;
Grant A
Mackenzie
;
Lucia
Mad'arová
;
Allison
McGeer
;
Tuya
Mungun
;
Jason M
Mwenda
;
J Pekka
Nuorti
;
Néhémie
Nzoyikorera
;
Kazunori
Oishi
;
Lucia Helena
De Oliveira
;
Metka
Paragi
;
Tamara
Pilishvili
;
Rodrigo
Puentes
;
Eric
Rafai
;
Samir K
Saha
;
Larisa
Savrasova
;
Camelia
Savulescu
;
J Anthony
Scott
;
Kevin J
Scott
;
Fatima
Serhan
;
Lena Petrova
Setchanova
;
Nadja
Sinkovec Zorko
;
Anna
Skoczyńska
;
Todd D
Swarthout
;
Palle
Valentiner-Branth
;
Mark
van der Linden
;
Didrik F
Vestrheim
;
Anne
von Gottberg
;
Inci
Yildirim
;
Kyla
Hayford
;
The Pserenade Team
;
(2021)
Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.
Microorganisms, 9 (4).
p. 742.
ISSN 2076-2607
DOI: 10.3390/microorganisms9040742
Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.
-
picture_as_pdf - microorganisms-09-00742 (1).pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0